Stabilized compositions comprising tissue factor pathway...

Details Stabilized compositions comprising tissue factor pathway... Stabilized compositions comprising tissue factor pathway...

2005-12-14

2010-02-09

Steadman, David J (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07659248

ABSTRACT:
Stabilized aqueous compositions of tissue factor pathway inhibitor (TFPI) or TFPI variants comprise a solubilizing agent, an antioxidant, and a buffer. The combination of a solubilizing agent and an antioxidant can lead to a significant improvement in the storage life of TFPI or TFPI variant compositions. The solubilizing agent and antioxidant substantially counteract the effects of TFPI or TFPI variant degradation through aggregation and oxidation.

REFERENCES:
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4812557 (1989-03-01), Yasushi et al.
patent: 4883661 (1989-11-01), Daly et al.
patent: 4894226 (1990-01-01), Aldwin et al.
patent: 4931543 (1990-06-01), Halenbeck et al.
patent: 5034225 (1991-07-01), Bennett et al.
patent: 5078997 (1992-01-01), Hora et al.
patent: 5272135 (1993-12-01), Takrurl
patent: 5340574 (1994-08-01), Maneglier et al.
patent: 5358708 (1994-10-01), Patel
patent: 5744132 (1998-04-01), Warne et al.
patent: 5763395 (1998-06-01), Blackburn et al.
patent: 5795779 (1998-08-01), McCormick et al.
patent: 5888968 (1999-03-01), Chen et al.
patent: 6248548 (2001-06-01), Veer et al.
patent: 6525102 (2003-02-01), Chen et al.
patent: 2002/0045571 (2002-04-01), Liu et al.
patent: 2002/0147184 (2002-10-01), Kosoglou et al.
patent: 2003/0092627 (2003-05-01), Petersen et al.
patent: 0 229 016 (1987-07-01), None
patent: 0 303 746 (1993-02-01), None
patent: 921124 (1992-10-01), None
patent: WO 9604377 (1996-02-01), None
patent: WO 96/40784 (1996-12-01), None
patent: WO 98/33920 (1998-08-01), None
patent: WO 99/51272 (1999-10-01), None
patent: WO 01/24814 (2001-04-01), None
patent: WO 0136632 (2001-05-01), None
patent: WO 02094864 (2002-11-01), None
GenCore search version 5.1.6, pp. 1-5.
Allen et al., “Hybrid (BDBB) Interferon-Alpha.: Preformulation Studies,”Int J Pharm, 1999, pp. 259-272, vol. 187.
Chang et al., “Development of a Stable Freeze-dried Formulation of Recombinant Human Interleukin-1 Receptor Antagonist,”Pharmaceutical Research, 1996, pp. 243-249, vol. 13.
Chen et al., “Solubility of Recombinant Human Tissue Factor Pathway Inhibitor,”Journal of Pharmaceutical Sciences, 1999, pp. 881-888, vol. 88.
Heller et al., “Manipulation of Lyophilization-Induced Phase Separation: Implications for Pharmaceutical Proteins,”Biotechnol Prog., 1997, pp. 590-596, vol. 13.
Taneja et al., “Increased Thermal Stability of Proteins in the Presence of Amino Acids,”Biochem J., 1994, pp. 147-153, vol. 303.
Wang et al., “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,”Journal of Parenteral Science and Technology, 1988, pp. S1-S26, vol. 42.

Affiliated with

Also associated with

Rating

Stabilized compositions comprising tissue factor pathway... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stabilized compositions comprising tissue factor pathway..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized compositions comprising tissue factor pathway... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4153580